Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The GALAD score identified patients with any stage HCC with an AUC of 0.96 - significantly greater than values for serum levels of AFP (AUC, 0.88), AFP-L3 (AUC, 0.86) or DCP (AUC, 0.87).
|
31712073 |
2020 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Alpha-fetoprotein is an autoantigen in hepatocellular carcinoma and juvenile Batten disease.
|
31585923 |
2020 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Analyses of HBV-related HCC specimens showed that the expression of AFP was negatively correlated with the levels of miR-1236 and miR-329.
|
31680299 |
2020 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Only <i>E-Cadherin</i> is an independent risk factor for prediction of HCC with low AFP.
|
31790342 |
2020 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In multivariate analysis, the CC genotype out-performed AFP is determining HCC.<b>Conclusion</b>: Apa1 CC genotype is linked to HCC in HCV C cirrhotic patients, and so has the potential to be an independent biomarker predictor for HCC occurrence in HCV cirrhosis.
|
31682785 |
2020 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
All studies provided the sensitivity and specificity of GPC3 and the alpha-fetoprotein (AFP) in the HCC and LC diagnosis.
|
31113610 |
2020 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The multivariable analysis, however, found that the association between TDF and HCC no longer existed (SHR, 0.81; 95% CI, 0.42-1.56; P = 0.52) after adjustment for age, sex, country, albumin, platelet, α-fetoprotein, cirrhosis, and diabetes mellitus.
|
31634265 |
2020 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The area under curves (AUC) was calculated for each microRNA and compared with that for alpha-fetoprotein (AFP) in the detection of HCC at early stage.
|
31053500 |
2020 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Independent predictors for HCC recurrence were male sex (p = 0.035), pre-operative liver cirrhosis (LC) (p = 0.025), serum creatinine > 1.5 mg/dL (p = 0.045), post-operative 5th-year alpha-fetoprotein (AFP) > 15 ng/ml (p < 0.001), LC (p = 0.004), and ALBI grades 2 and 3 (p < 0.001).
|
31559485 |
2020 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Clinical value of LHPP-associated microRNAs combined with protein induced by vitamin K deficiency or antagonist-II in the diagnosis of alpha-fetoprotein-negative hepatocellular carcinoma.
|
31693242 |
2020 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This model may enhance early-stage HCC detection and help to overcome insufficient sensitivity of AFP.
|
31648804 |
2020 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Prognostic stratification of patients undergoing resection for HCC within and beyond the BCLC resection criteria should include assessment of AFP and comorbidities for BCLC-0/A patients, as well as tumor burden for BCLC-B patients.
|
31696396 |
2020 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Taken together, AFP and ORM1 in the urine may be used as a diagnostic or screening biomarker of HCC and studies on large samples are needed to validate the result.
|
31736338 |
2020 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
A model combining these 4 MRI factors with alpha-fetoprotein level had the best performance in predicting the identification of IDNs as HCCs in explanted livers.
|
31756026 |
2020 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
High UBE2Z expression was significantly correlated with age, advanced TNM stage, histological grade, vascular invasion, elevated serum alpha-fetoprotein expression (AFP), worse overall survival (OS) and disease-free survival (DFS) of HCC patients (all P < 0.05).
|
31831168 |
2020 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The overall Hepatocellular carcinoma (HCC) was found to be positively correlated with alkaline phosphatase, γ-glutamyltransferase, and alpha-fetoprotein and liver stiffness measurement values from stage A to stage D (P < .05).
|
31659795 |
2020 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In down-staging groups, AFP ≥ 100 (HR, 2.6; P = 0.02) was the only independent predictor of HCC recurrence.
|
31344273 |
2020 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
AFP acetylation plays an important role in HCC progression and provides a new potential prognostic marker and therapeutic target for HCC.
|
31811908 |
2020 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The area under the curve of MRI alone and combination with AFP was not statistically different (Any-HCC: 0.905 vs. 0.924; Early-HCC: 0.853 vs. 0.885; Very early-HCC: 0.838 vs. 0.885, respectively, all P values >0.2).
|
31524775 |
2020 |
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Significant predictors for HCC were identified using multiple Cox regression analysis in study cohort: treatment age ≥60 years (hazard ratio [HR]: 2.04, 95% confidence interval [CI] = 1.3-3.7), pretreatment bilirubin ≥1.1 mg/dL (HR: 1.99, 95% CI = 1.08-3.67), α-fetoprotein ≥7.9 ng/mL (HR: 2.44, 95% CI = 1.16-5.32), no sustained virological response (SVR; HR: 1.91, 95% CI = 1.05-3.45), and baseline cirrhosis (HR: 4.45, 95% CI = 2.07-9.73).
|
31800346 |
2020 |
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
CircPanel showed a higher accuracy than AFP (alpha-fetoprotein) to distinguish individuals with HCC from controls in all three sets (AUC, 0.863 [95% confidence interval, CI: 0.819-0.907] vs. 0.790 [0.738-0.842], p = 0.036 in training set; 0.843 [0.796-0.890] vs. 0.747 [0.691-0.804], p = 0.011 in validation set 1 and 0.864 [0.830-0.898] vs. 0.769 [0.728-0.810], p < 0.001 in validation set 2).
|
31456215 |
2020 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The results showed that TRIM7 expression was elevated in human HCC tissues and that TRIM7 expression was significantly associated with tumor size, pTNM stage, serum α-fetoprotein (AFP) concentration, serum hepatitis B virus (HBV) DNA copy number and overall survival (OS) of HCC patients.
|
30850165 |
2019 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Protein induced by vitamin K antagonist-II (PIVKA-II), in addition to alpha-fetoprotein, is a useful tumor marker for diagnosis of hepatocellular carcinoma (HCC).
|
31131509 |
2019 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Postoperative α-fetoprotein response predicts tumor recurrence and survival after hepatectomy for hepatocellular carcinoma: A propensity score matching analysis.
|
30846192 |
2019 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our study aims to detect the sensitivity of the new biomarker miR-212 existing in serum exosomes along with other hepatocellular carcinoma biomarkers such as AFP (alpha-fetoprotein), CA125 (carbohydrate antigen-ca125), and Hbx protein in the diagnosis of HBV-related liver diseases.
|
31608838 |
2019 |